Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Score 0 points
Score 1 point
Score 2-3 points
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.